NCT03661541View on ClinicalTrials.gov

Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 2, 2017

Primary Completion Date

June 17, 2017

Study Completion Date

October 25, 2017

Conditions
HSVHerpes Labialis
Interventions
DRUG

Squaric Acid Dibutyl Ester

2% squaric acid dibutyl ester (SADBE) (Supplied by Squarex) is topically applied to the inner aspect of the upper arm of the subject and covered with Tegaderm. Subject is advised to wash it off after 3 hours.

Trial Locations (1)

55114

Prism Clinical Research, LLC, Saint Paul

All Listed Sponsors
lead

Squarex, LLC

INDUSTRY

NCT03661541 - Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1) | Biotech Hunter | Biotech Hunter